Progyny, Inc. (PGNY): what the price assumes

In the published model solve dated 2026-Q2, anchored at $31.34, Progyny, Inc. (PGNY) is priced for today's economics sustained for ~5.3 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-28.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/PGNY

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 6: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 10.1% cost of capital; growth searched up to the 26.7% self-funding ceiling; each 1pp moves the implied horizon ~1.5 years.

How unusual the bet is: within-range

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=18)

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Progyny sells fertility benefits to large employers, providing self-insured enterprise clients and their members with fertility coverage through a managed clinic network, and it has grown to more than "530 employers, each with at least 1,000 covered lives" across roughly 6.7 million lives.
• The business is profitable and self-funded, holding about $225 million in net cash with no debt, and it has been shrinking its share count, retiring 8.8 million shares under a completed $200 million buyback.
• The defining risk is client concentration and employment-linked demand, made concrete by the non-renewal of a large client that cost roughly $31 million in revenue, the kind of loss that can swing a single year.

Bull Case

The balance sheet tells you what kind of company Progyny is, and it is an unusual one for a fast-growing health business: it funds itself. Progyny holds about $225 million in net cash with no debt, which means its growth is paid for out of its own cash flow rather than by issuing stock or borrowing. More telling, the company has been returning capital, completing a $200 million share repurchase that retired 8.8 million shares, shrinking the count about 4%. A growth company buying back stock rather than diluting is a signal that management believes the shares are cheap and that the business throws off more cash than it needs, which is rare in a sector where most growth names burn cash and dilute.

The model underneath generates that cash because it sits between large employers and fertility providers without taking on insurance risk in the traditional sense. Progyny serves, per the 10-K, more than "530 employers, each with at least 1,000 covered lives" and holds contracts covering roughly 6.7 million employees and dependents. It is paid by self-insured employers to manage a benefit those employers want to offer to attract and retain talent, and it bundles a managed network of clinics with a member-support layer. As more employers add fertility coverage, and as members within existing clients use it, Progyny grows on two axes at once, new clients and rising utilization inside the existing book.

The financials show the model working at scale. Revenue grew about 12% year over year excluding a large client that did not renew, and the company guides full-year 2026 revenue toward roughly $1.37 billion to $1.41 billion with adjusted EBITDA of about $232 million to $244 million. The growth-oriented and peer-multiple methods reach the price, crediting that continued expansion, and analysts have turned more positive, with Citi upgrading to Outperform and Jefferies setting a $30 target. For a profitable, net-cash, buyback-deploying benefits platform with a long runway of employers yet to add the benefit, the bull case is durable double-digit growth funded entirely from within.

Bear Case

The bear case starts with the fact that Progyny's demand is tied to employment and to a concentrated client base, and the most recent year showed exactly how that bites. A single large client did not renew, costing roughly $31 million in revenue, enough to mask the underlying growth in the headline number. The 10-K is candid that the business depends on its ability "to retain existing clients and attract new clients" and on "the level and mix of utilization of our solutions by members," and it flags that pricing pressure or shifts within the technology industry could hurt results. That last point matters: Progyny's client base skews toward large, well-paying employers, many in tech, and when those employers cut headcount or trim benefits in a downturn, both the covered-life count and the utilization that drives revenue fall together.

The valuation does not fully discount that cyclicality. At today's price the asset-based and earnings-power methods read expensive: the stock trades at a large multiple of its book value of about $5.18 per share, and capitalizing its normalized operating earnings at the cost of capital lands far below the price. The price embeds an operating-income growth assumption above 20%, well above the roughly 12% revenue growth the company is currently posting, which means the market is paying for both continued client wins and margin expansion. Fertility benefits are also a discretionary cost for employers, the kind of perk that gets added in a tight labor market and scrutinized in a loose one, so the addressable demand is not as recession-proof as a core health benefit.

There is also a quality-of-earnings wrinkle the headline numbers obscure. Stock-based compensation is a large share of the gap between reported free cash flow and the cash that actually accrues to shareholders: adjusting free cash flow for stock-based comp cuts it substantially, which means a meaningful portion of the company's economics is being paid to employees in equity rather than retained for owners. The buyback partly offsets that dilution, but it is also, in part, mopping up the shares that compensation creates. The bear case is a good business at a full price: a discretionary, concentration-exposed benefit priced for sustained 20%-plus profit growth, where a couple of large client losses or a labor-market downturn could interrupt the compounding the price assumes.

Valuation

The price is betting on durable growth: that Progyny keeps winning employer clients and lifting utilization inside its existing book, sustaining operating-income growth above 20% even though current revenue growth runs closer to 12%. The inversion frames the bet as growth-led, not margin-led, which fits a company still early in penetrating the employer market for fertility coverage but means the price requires the client-and-utilization engine to keep running well above the maturing pace.

The methods split the way they do for a profitable growth company. The relative-multiple lens and the growth-oriented methods reach the price, crediting the forward expansion, with the peer-multiple read landing near where the stock trades. The static lenses say expensive: the asset-based methods, anchored on a thin book value of about $5.18 per share, and the earnings-power methods, which capitalize the modest current operating profit with no growth, both land well below the price. That divergence is the standard signature of a growth name, the market is paying for what the business becomes, not what its trailing earnings are. The free-cash-flow method, notably, lands close to the price on a headline basis but far below once stock-based compensation is deducted, which is the single most important caveat in the valuation: the cash the business generates for shareholders is materially smaller than the headline free cash flow suggests.

Solvency is a genuine strength and bounds the downside cleanly. Progyny holds about $225 million in net cash with no debt, so there is no financial risk and no funding dependency, and the share count is falling about 4% a year through buybacks. For a company with no leverage, the balance-sheet frame is capital-return capacity, and Progyny is deploying it. What the buyer is underwriting is not a balance-sheet risk but a growth-durability bet: the client wins and utilization have to keep compounding to justify a price that assumes 20%-plus profit growth, against a demand base that is discretionary, employment-linked, and concentrated enough that one large client's exit moves the numbers. The net cash is the floor; the growth assumption is the variable.

Catalysts

Progyny's Q1 2026 print showed the underlying growth holding up despite a notable client loss. Revenue grew about 12% year over year after excluding roughly $31 million from a large client that did not renew, and the company completed its $200 million share repurchase, retiring 8.8 million shares including 5.5 million bought for about $116 million in the quarter. For full-year 2026, management guides to revenue of roughly $1.37 billion to $1.41 billion, net income of about $104 million to $112 million, and adjusted EBITDA of about $232 million to $244 million. The next quarterly prints are the read on whether new-client wins and utilization fully offset the lapped client loss and whether the growth reaccelerates as the comparison normalizes.

The swing factors are client retention, utilization, and the labor market. Management maintained its utilization and assisted-reproductive-technology consumption assumptions, so any change there would move the model, and the selling season for new employer clients each year is the key growth catalyst to watch. Analyst sentiment has improved, with Citigroup upgrading the stock to Outperform and Jefferies setting a $30 price target with a Buy rating. The developments that matter are the pace of new employer signings ahead of the next benefit year, the trend in covered lives as clients adjust headcount, and any further large-client renewals or losses, since concentration means a single contract can shift a year's growth meaningfully.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• PRVA (Privia Health Group, Inc.)
• FY2025 10-K: …locations maintain their legacy brand, but also adopt the overarching Privia Medical Group brand. Competitive Landscape We compete in a highly fragmented and competitive U.S. healthcare industry. We face competition in each geographic market from a variety of community-based healthcare provider organizations,…
• FY2025 10-K: …customers, or payers than we do. In addition, some of our competitors have been in business longer than we have or may have more mature or effective tools, strategies and procedures. Generally, other medical groups and healthcare providers in the markets our Medical Groups serve provide services similar to those our…
• HIMS (HIMS & HERS HEALTH, INC.)
• FY2025 10-K: …put us at a competitive disadvantage. Our ability to compete effectively depends on our ability to distinguish our company and our offerings from our competitors and their products, and includes factors such as: • accessibility, ease of use and convenience; • price and affordability; • personalization; • brand…
• FY2025 10-K: …competitive solutions. In addition, the entry of multiple new products may lead some of our competitors to employ pricing strategies that could adversely affect the pricing of products and services we make available. If a competitor develops a product or business that competes with or is perceived to be superior to…
• OPCH (OPTION CARE HEALTH, INC.)
• FY2025 10-K: …of this bidding process, we may not be retained, and even if we are retained, the prices at which we are able to retain the business may be reduced. The loss of a payer relationship could significantly reduce the number of patients we serve and have a material adverse effect on our revenue and net income, and a…
• FY2025 10-K: …and deciding on how to allocate resources such as capital investments, share repurchases, and acquisitions. The CODM does not use or receive total assets by segment to make decisions regarding resources; therefore, the total asset disclosure by segment has not been included. The following table reflects results of…
• CHE (CHEMED CORPORATION)
• FY2025 10-K: …in reliance on contract nurses could negatively impact profitability. VITAS may not be able to compete successfully against other hospice providers, and competitive pressures may limit its ability to maintain or increase its market position, which could adversely affect its profitability, financial condition and cash…
• FY2025 10-K: …Roto-Rooter's revenue and operating results are impacted by significant weather patterns across the United States. Significant changes in precipitation or temperatures in areas we have company-owned and Independent Contractor operations will generally affect the revenue and operating results at Roto-Rooter. A…
• MD (Pediatrix Medical Group, Inc.)
• FY2025 10-K: …of the applicable practice group. See "Government Regulation-Fee Splitting; Corporate Practice of Medicine." COMPETITION The physician services industry is highly fragmented. Competition in our business is generally based upon a number of factors, including reputation, experience and level of care and our affiliated…
• FY2025 10-K: …Economic Conditions and Other Factors Our operations and performance depend significantly on economic conditions. During the year ended December 31, 2025, the percentage of our patient service revenue being reimbursed under government-sponsored or government-funded healthcare programs ("GHC Programs") remained stable…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.